Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18977838 | LEONURINE NANOCOMPOSITE HYDROGEL AND PREPARATION METHODS AND APPLICATIONS THEREOF | December 2024 | April 2025 | Allow | 4 | 1 | 0 | No | No |
| 18761898 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | July 2024 | January 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18762128 | MANUFACTURING OF BUPIVACAINE MULTIVESICULAR LIPOSOMES | July 2024 | February 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18565894 | CATIONIC LIPID COMPOUND, COMPOSITION CONTAINING SAME AND USE THEREOF | November 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18038871 | PEPTIDE HAVING PROTECTIVE ACTIVITY AGAINST CELL DAMAGE CAUSED BY PARTICULATE MATTER, AND USES FOR SAME | May 2023 | July 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18321613 | PREPARATION METHOD AND APPLICATION OF TUMOR MICROPARTICLES ENCAPSULATING METABOLIC INHIBITORS | May 2023 | June 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 18156534 | SKIN WHITENING COMPOSITION | January 2023 | April 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18081752 | COSMETIC COMPOSITION COMPRISING POLYACRYLATE CROSSPOLYMER-6, AND SILICA AND/OR LAUROYL LYSINE | December 2022 | February 2025 | Abandon | 26 | 3 | 0 | No | No |
| 17994217 | SUSTAINED-RELEASE PHEROMONE PREPARATION | November 2022 | June 2025 | Allow | 30 | 3 | 0 | Yes | No |
| 17979303 | COSMETIC PRODUCT COMPRISING OIL DISCONTINUOUS PHASE AND METHOD OF USE THEREOF | November 2022 | May 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17978667 | PRODUCTION PROCESS OF A CONVENIENT AND QUICK-ADHESIVE EYELASHES | November 2022 | April 2024 | Abandon | 17 | 1 | 0 | No | No |
| 17970649 | SKIN HEALTH PRESERVATION TREATMENT FORMULATION | October 2022 | October 2024 | Abandon | 23 | 2 | 1 | No | No |
| 17957707 | ACIDIC BONDING COMPOSITIONS AND METHODS FOR RESTORING AND COLOR TONING LIGHTENED HAIR | September 2022 | January 2025 | Allow | 27 | 3 | 1 | Yes | Yes |
| 17956528 | PHARMACEUTICAL FORMULATION CONTAINING A PSYCHEDELIC SUBSTANCE OBTAINED BY SELECTIVE LASER SINTERING (SLS) 3D PRINTING | September 2022 | August 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17812746 | HEMOSTATIC NANOCAPSULES FOR STOPPING BLEEDING, VISUALIZING INJURY, AND DELIVERING DRUGS | July 2022 | August 2024 | Allow | 25 | 1 | 1 | No | No |
| 17843703 | FULLERENE GALLIUM PHOSPHONATE AND METHODS | June 2022 | June 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17774575 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | May 2022 | May 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17737982 | LIGHT STABLE SILVER CONTAINING NEAR NEUTRAL pH DISINFECTANT AND METHOD OF PREPARATION | May 2022 | August 2024 | Allow | 27 | 1 | 0 | No | No |
| 17771856 | STABILIZED AMORPHOUS CALCIUM MAGNESIUM PHOSPHATE PARTICLE COMPOSITIONS | April 2022 | April 2025 | Allow | 35 | 0 | 1 | No | No |
| 17768543 | PERSONAL CARE FORMULATION | April 2022 | April 2025 | Allow | 36 | 1 | 0 | No | No |
| 17765893 | THREE-DIMENSIONAL FLOW PATH STRUCTURE BODY AND NANOPARTICLE PRODUCTION METHOD USING SAME | April 2022 | May 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17764432 | ANTI-UV COSMETIC COMPOSITION | March 2022 | May 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17640749 | EXTRACELLULAR VESICLE-FENRETINIDE COMPOSITIONS, EXTRACELLULAR VESICLE-C-KIT INHIBITOR COMPOSITIONS, METHODS OF MAKING AND USES THEREOF | March 2022 | March 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17597232 | ISOXAZOLINE COMPOUNDS AND USE THEREOF | December 2021 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17615967 | OIL-IN-WATER TYPE EMULSION LIP COSMETIC | December 2021 | June 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17595156 | LIPID NANOPARTICLE | November 2021 | May 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17609958 | MICROPARTICLES COMPRISING CELLULOSE NANOCRYSTALS AGGREGATED WITH PROTEINS AND COSMETIC USES THEREOF | November 2021 | December 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17437290 | EYE DROPS CONTAINING CHITOSAN NANOPARTICLES IN WHICH PDRN IS ENCAPSULATED, AND PREPARATION METHOD THEREFOR | November 2021 | May 2025 | Allow | 45 | 2 | 0 | No | No |
| 17606718 | PRODUCTS OF MANUFACTURE AND METHODS FOR TRANSDERMAL DELIVERY OF PHARMACEUTICALS, ELECTROLYTES, AND NUTRICEUTICALS | October 2021 | January 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17603339 | USE OF GOLD NANOCLUSTERS IN TREATING HYPERCHOLESTEROLEMIA OR HYPERCHOLESTEROLEMIA-ASSOCIATED DISEASES | October 2021 | May 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17601144 | ANTISEPTIC SKIN PREP COMPOSITION | October 2021 | April 2025 | Allow | 42 | 2 | 0 | No | No |
| 17600965 | SOLID NANOPARTICLE FORMULATION OF WATER INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD RIPENING AND IMMEDIATE DRUG RELEASE FOLLOWING INTRAVENOUS ADMINISTRATION | October 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17593981 | PERSONAL CARE COMPOSITIONS AND METHODS COMPRISING TRANS-1-CHLORO-3,3,3-TRIFLUOROPROPENE AND TRANS-1,3,3,3-TETRAFLUOROPROPENE | September 2021 | April 2025 | Abandon | 43 | 2 | 0 | No | No |
| 17598956 | COSMETIC COMPOSITION | September 2021 | June 2025 | Allow | 44 | 2 | 0 | Yes | No |
| 17442949 | Method of Making Prodrug for Sustained and Controlled Release | September 2021 | November 2024 | Allow | 37 | 1 | 0 | No | No |
| 17442746 | Doxorubicin Containing Nanoplexes and Uses Thereof | September 2021 | April 2025 | Allow | 42 | 1 | 1 | No | No |
| 17439911 | NANOPARTICLE, METHOD FOR PRODUCING NANOPARTICLE, AND PHARMACEUTICAL COMPOSITION | September 2021 | November 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17438892 | TRANSPARENT OR SEMITRANSPARENT INVERSE MICROLATICES OF POLYACRYLAMIDE AS OIL EMULSION DRIFT REDUCING AGENT | September 2021 | May 2025 | Allow | 44 | 2 | 0 | No | No |
| 17401654 | CIPROFLOXACIN POLYMORPH AND ITS USE | August 2021 | October 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17430497 | BIOBASED PEARLESCENT WAXES | August 2021 | April 2025 | Allow | 44 | 2 | 1 | No | No |
| 17400376 | Late-Stage Product Differentiation Process for Personal Care Products | August 2021 | June 2024 | Allow | 34 | 1 | 0 | Yes | No |
| 17310351 | PARTICLES OF A MIXTURE OF IRON(III)-OXYHYDROXIDE, SUCROSE AND ONE OR MORE STARCHES, PREFERABLY OF SUCROFERRIC OXYHYDROXIDE | July 2021 | March 2025 | Allow | 43 | 1 | 1 | No | No |
| 17423862 | Production and Use of Yeast Extract as a Medical Adjuvant | July 2021 | April 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17251521 | POLYION COMPLEX MICELLE THAT INCLUDES ANTISENSE OLIGONUCLEOTIDE AND BLOCK COPOLYMER OF PEG BLOCK AND CATIONIC POLYMER, SAID BLOCK COPOLYMER HAVING NUMBER-AVERAGE MOLECULAR WEIGHT OF 3-10 kDa | July 2021 | September 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17417160 | OIL-IN-WATER TYPE PEST REPELLENT COMPOSITION | June 2021 | June 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17417263 | METHOD FOR CONTROLLING WEED | June 2021 | August 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17415204 | Biofertilizing Bacterial Strain | June 2021 | February 2025 | Allow | 44 | 1 | 0 | No | No |
| 17413104 | DEPOSITION SYSTEM FOR HAIR | June 2021 | March 2025 | Allow | 45 | 2 | 0 | No | No |
| 17413361 | DEPOSITION SYSTEM FOR HAIR | June 2021 | December 2024 | Allow | 42 | 2 | 1 | No | No |
| 17312579 | ANTIMICROBIAL IMPLANTABLE MEDICAL DEVICES | June 2021 | March 2025 | Abandon | 46 | 2 | 0 | Yes | No |
| 17311528 | CANNABIS-BASED SELF-EMULSIFYING PRODUCT | June 2021 | July 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17311129 | HIGH-CONTENT AND SUSTAINED-RELEASE RETINOID CAPSULE, AND COMPOSITION FOR REDUCING WRINKLES, CONTAINING SAME | June 2021 | April 2025 | Allow | 46 | 3 | 0 | No | No |
| 17311010 | BIOCOMPATIBLE STRUCTURE COMPRISING HOLLOW CAGE, AND MANUFACTURING METHOD THEREFOR | June 2021 | August 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17311145 | METHOD FOR FORMING COATING FILM | June 2021 | June 2025 | Allow | 49 | 3 | 0 | Yes | No |
| 17296725 | COATING FILM FOR SKIN | May 2021 | January 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17295284 | METHOD FOR TREATING HAIR, COMPRISING THE APPLICATION OF COATED PIGMENTS AND SILANES | May 2021 | June 2024 | Abandon | 37 | 2 | 0 | No | No |
| 17316857 | METHOD FOR AUTOMATICALLY PRODUCING INDIVIDUALIZED TABLETS, AND TABLET PRESS FOR AUTOMATICALLY PRODUCING INDIVIDUALIZED TABLETS | May 2021 | January 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17307605 | NANOPARTICLE FORMULATIONS OF IKE AND METHODS OF USE THEREOF | May 2021 | July 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17290773 | PH-SENSITIVE CARBON NANOPARTICLES, PREPARATION METHOD THEREFOR, AND DRUG DELIVERY USING SAME | May 2021 | May 2025 | Allow | 48 | 3 | 0 | No | No |
| 17290206 | COMPOSITION OF ACTIVE INGREDIENTS, FOR CARE AND SURFACE MODIFICATION OF HUMAN HAIR | April 2021 | October 2024 | Abandon | 42 | 2 | 0 | No | No |
| 17288983 | OIL-IN-WATER-TYPE SKIN EXTERNAL AGENT | April 2021 | March 2025 | Abandon | 46 | 3 | 0 | No | No |
| 17289117 | MEDICAL DEVICE AND METHOD FOR PRODUCING THE SAME | April 2021 | July 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17288168 | COMPOSITION COMPRISING AT LEAST ONE SILICONE ACRYLIC COPOLYMER AND AT LEAST ONE CATIONIC ACRYLIC COPOLYMER | April 2021 | December 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17285623 | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING AN IMMUNOMODULATING AGENT AND USES THEREOF | April 2021 | December 2024 | Allow | 44 | 2 | 1 | No | No |
| 17284841 | Tunable Process for Silica Capsules/Spheres Preparation and Their Use | April 2021 | October 2024 | Allow | 42 | 2 | 0 | No | No |
| 17283103 | COMPOSITION FOR TREATMENT OF VITREOUS DISEASE OR DISORDER | April 2021 | May 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17207847 | Gelled Aerosol Product and Gel Forming Kit | March 2021 | January 2025 | Abandon | 46 | 2 | 0 | Yes | No |
| 17274555 | METHOD OF MAKING ORAL DOSAGE FORMS | March 2021 | June 2025 | Allow | 51 | 2 | 0 | Yes | No |
| 17270747 | SUSTAINED-RELEASE OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | February 2021 | January 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17269972 | CANNABINOID BASED EMULSION SYSTEMS FOR INFUSED AQUEOUS COMPOSITIONS | February 2021 | July 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17269573 | SUNCARE FORMULATION | February 2021 | October 2024 | Allow | 44 | 4 | 0 | No | No |
| 17269574 | COLOR COSMETIC FORMULATION | February 2021 | September 2024 | Allow | 43 | 3 | 0 | No | No |
| 17258630 | COMPOSITION COMPRISING A SILICONE/POLYUREA OR SILICONE/POLYURETHANE COPOLYMER OR SILICONE/POLYUREA/POLYURETHANE COPOLYMER, A SILICONE RESIN, A VOLATILE ALKANE AND A C2-C8 MONOALCOHOL | January 2021 | April 2024 | Abandon | 39 | 1 | 0 | No | No |
| 16971158 | RADIATION-TRIGGERED LIPOSOMES | August 2020 | September 2024 | Allow | 49 | 1 | 0 | No | No |
| 16480864 | MULTI-ARM BLOCK-COPOLYMERS FOR MULTIFUNCTIONAL SELF-ASSEMBLED SYSTEMS | July 2019 | September 2024 | Allow | 60 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LIPPERT, JOHN WILLIAM.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LIPPERT, JOHN WILLIAM works in Art Unit 1615 and has examined 72 patent applications in our dataset. With an allowance rate of 50.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner LIPPERT, JOHN WILLIAM's allowance rate of 50.0% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LIPPERT, JOHN WILLIAM receive 1.57 office actions before reaching final disposition. This places the examiner in the 40% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by LIPPERT, JOHN WILLIAM is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +44.3% benefit to allowance rate for applications examined by LIPPERT, JOHN WILLIAM. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 41.0% of applications are subsequently allowed. This success rate is in the 91% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 33.3% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 28.6% are granted (fully or in part). This grant rate is in the 19% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.